Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020236 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
A Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 944
- Enrollment target
- 20
- Study locations
NCT05020236: Recruiting Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
NCT05020236 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 944 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05020236, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 944 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Daratumumab
- DRUG Pomalidomide
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Aventura - Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center - Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs - Coral Springs
- University of Miami Hospital and Clinics - Deerfield Beach - Deerfield Beach
- Sylvester Comprehensive Cancer Center - Hollywood - Hollywood
- Griffin Cancer Research Building (GCRB) - Miami
- Sylvester Comprehensive Cancer Center - Miami
- University of Miami Hospital and Clinics - Miami
- Sylvester Comprehensive Cancer Center - Kendall - Miami
- Sylvester Comprehensive Cancer Center - Plantation - Plantation
California
- Clovis Community Medical Center - Clovis
- Community Cancer Institute - Clovis
- University of California San Francisco - Fresno
- Community Regional Medical Center - Fresno
Colorado
- UCHealth Poudre Valley Hospital - Fort Collins
- UCHealth Harmony - Fort Collins
- UCHealth Greeley Hospital - Greeley
- UCHealth - Medical Center of the Rockies - Loveland
Louisiana
- East Jefferson General Hospital - Metairie
New Jersey
- MSK Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 944 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 3 |
What NCT05020236 shows while recruiting
NCT05020236 is an interventional study that assigns participants to a tested intervention. The registered 944 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT05020236 names 20 study sites across 5 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05020236 about?
NCT05020236 is a clinical study titled "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments". The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of el...
What is the current status of trial NCT05020236?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 944 participants. The study started on 2021-10-04. Estimated completion is 2027-05-31.
What conditions does trial NCT05020236 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05020236?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT05020236?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020236 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05020236's enrollment target sits among peer trials
944 25th of 438 higher than 414 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI